Orphan Drug Report 2024
Orphan Drugs are Losing Their Sparkle
For more than a decade, orphan drugs’ growth has outpaced that of non-orphan prescription drugs. Niche products’ share of worldwide prescription drug sales by value has doubled over the last decade, from less than 10% in 2014 to almost a fifth...
Orphan Drugs Are Losing Their Sparkle
Top Ten Orphans In 2028: Shake Up
Countervailing IRA Winds
The Orphan Pipeline – The ‘Vanza Triple’ Dominates
Company Rankings – Amgen Replaces AbbVie in Top Ten Company Ranking
Move Over, Oncology…
Amid Policy Fights, Orphans’ Share May Stabilise
HOW WE HELP
Appendix